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ABSTRACT—Introduction: Antimicrobial resistance threatens to undermine treatment of severe infection; new therapeutic
strategies are urgently needed. Preclinical work shows that augmented passive immunotherapy with P4 peptide increases
phagocytic activity and shows promise as a novel therapeutic strategy. Our aim was to determine ex vivo P4 activity in a
target population of patients admitted to critical care with severe infection.Methods: We prospectively recruited UK critical
care unit patients with severe sepsis and observed clinical course (!3 months postdischarge). Blood samples were taken in
early ("48h postdiagnosis, n¼54), latent (7 days postdiagnosis, n¼39), and convalescent (3–6 months postdiagnosis,
n¼18) phases of disease. The primary outcome measure was killing of opsonized Streptococcus pneumoniae by
neutrophils with and without P4 peptide stimulation. We also used a flow cytometric whole blood phagocytosis assay to
determine phagocyte association and oxidation of intraphagosomal reporter beads. Results: P4 peptide increased
neutrophil killing of opsonized pneumococci by 8.6% (confidence interval 6.35–10.76, P<0.001) in all phases of sepsis,
independent of infection source and microbiological status. This represented a 54.9% increase in bacterial killing compared
with unstimulated neutrophils (15.6%) in early phase samples. Similarly, P4 peptide treatment significantly increased
neutrophil and monocyte intraphagosomal reporter bead association and oxidation, independent of infection source.
Conclusions: We have extended preclinical work to demonstrate that P4 peptide significantly increases phagocytosis and
bacterial killing in samples from a target patient population with severe sepsis. This study supports the rationale for
augmented passive immunotherapy as a therapeutic strategy in severe sepsis.
KEYWORDS—Bacterial infection, innate immunity, neutrophil biology
INTRODUCTION
Severe sepsis is a worldwide public health concern despite
recent advances and standardization in treatment (1–3). The
current evidence base for effective therapies is limited to
antibiotics, source control, and organ support (4). In this
context, antimicrobial resistance is of immediate concern
and has been described as ‘‘a threat to national security’’ by
prominent health leaders (5). Augmented passive immunother-
apy using a peptide fragment of pneumococcal surface adhesin
A (PsaA) to stimulate phagocytic cells is one alternative
therapeutic strategy that shows promise (6).
P4 peptide is a 28–amino acid fragment of PsaA, a protein
expressed on the surface of Streptococcus pneumoniae. Initially
investigated as a vaccine candidate, it was discovered that P4
peptide stimulation promotes increased bacterial (including
S pneumoniae, Streptococcus pyogenes,Neisseria meningitidis,
and Staphylococcus aureus) binding by phagocytic cells (7, 8).
Following this, multiple in vivo investigations have shown that
the administration of P4 peptide in combination with immu-
noglobulin rescues moribund mice from death in streptococcal
and staphylococcal infection models (8–14). Furthermore,
healthy human alveolar macrophages demonstrate improved
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bacterial killing when exposed to P4 peptide ex vivo (15).
However, patients with severe infection develop marked
immune dysregulation, negatively impacting on innate and
adaptive immune function (16). Thus, it is unclear if the effects
of P4 peptide observed in vitro and in vivowill also apply to our
target population—patients with severe sepsis.
The aim of our study was to test the effect of P4 peptide on
phagocytic cells ex vivo from patients admitted to critical care
with severe sepsis. Determination of P4 peptide activity in this
target population will support the translation of this promising
therapeutic strategy to future clinical trials and clinical utility.
PATIENTS AND METHODS
Clinical
We recruited patients admitted to critical carewith severe sepsis according to
ACCP-SCCM 2001 criteria (17) at Aintree University Hospital and Royal
Liverpool University Hospital, UK (February 2014 to June 2015). Patient
inclusion criteria were as follows: age !18, recruitment "48 h diagnosis,
and severe sepsis from respiratory, abdominal, or urogenital source (predom-
inant causes (18)). Patient exclusion criteria were as follows: immunocom-
promising condition or therapy, pregnancy, responsible clinician deemed
inappropriate, coenrolment in another study that could have influenced results,
or failure to obtain consent. Blood samples were taken at days 0 and 7, and at 3
to 6 months to determine phagocyte function in the early, latent, and con-
valescent phases of infection. Previous work has demonstrated suppression of
neutrophil response in the latent phase of infection (19). Our aim was to capture
this phase to determine peptide activity and follow with convalescent samples
after patients had been discharged home. Healthy volunteers were recruited and
sampled at matched intervals (Clinical Research Facility, Royal Liverpool
University Hospital) to determine assay stability and validate components.
Healthy volunteer inclusion criteria were as follows: no current illness, aged
>18, and able to travel to the research facility. Healthy volunteer exclusion
criteria were the same as for patients. The UKNHS Research Ethics Committee
granted approval for this project (13/WA/0353). Written consent was obtained
for all participants. A CONSORT diagram that details patient screening and
inclusion is provided in Figure S1 (Supplemental Digital Content, http://links.
lww.com/SHK/A443).
Laboratory
P4 peptide andM12-1 peptide were synthesized and purified by Centers for
Disease Control, Atlanta, Ga, and reconstituted in diethylpyrocarbonate
(DEPC) water. The primary outcome measure was neutrophil bacterial killing
determined by a standardized opsonophagocytosis assay (with minor modi-
fications (20)). Briefly, neutrophils were isolated from heparinized blood by
density centrifugation and incubated (45min, 378C, shaking 300 RPM) with
live pneumococci (capsulated serotype 2, D39 strain), human intravenous
immunoglobulin (IVIG; Gamunex, Grifols Inc, Spain), baby rabbit comp-
lement (Mast Group, Bootle, UK), and P4 peptide (1mg/mL) or control (M12-
1 peptide 1mg/mL and DEPC vehicle). The dose of P4 peptide in this assay
was based on previously published work (8). The multiplicity of infection was
100:1 (neutrophil:bacteria). Plates were cooled (48C) to arrest phagocytic
activity and the mixture incubated for 18 to 24 h (blood agar, 378C, 5% CO2)
before colony-forming unit enumeration. All samples were performed in
triplicate. Neutrophil bacterial killing index is defined as follows: 1$ (exper-
(experimental well divided by non-ploymorphonuclear leukocytes [PMN]
control well). Experimental components were neutrophils (PMN), opsonized
bacteria, and complement with P4 peptide, M12-1 peptide, or vehicle control.
Non-PMNcomponents were opsonized bacteria and complement. See Supple-
mental Digital Content, http://links.lww.com/SHK/A443, for full details of
experimental methods.
Our whole blood phagocytosis assay is built on previous work (21). After
venepuncture, citrated blood (4.5mL, BD) was placed on an automated mixer
at room temperature. The intraphagosomal reporter beads constitute immu-
noglobulin G–coated silica beads with calibrator (Pacific Blue, Invitrogen,
USA) and reporter (OxyBURST Green, Invitrogen, USA) fluorochromes.
Beads were reconstituted (30% 106/mL) in Roswell Park Memorial Institute
media (Invitrogen, USA) and mixed with experimental solution (4mg/mL
P4 peptide or plain DEPC), 5:1 ratio. This dose was based on a P4 peptide
titration experiment (Supplemental Digital Content, http://links.lww.com/
SHK/A443). Subsequently, paired 120mL aliquots (0, 10, 20, 30, 45, and
60min) were incubated with whole blood (100mL) at 378C in the dark.
Multiple fluorescence minus one controls were used to set negative and
positive boundaries for analysis (Fig. S2, Supplemental Digital Content,
http://links.lww.com/SHK/A443). After allotted incubation time, samples
were rapidly cooled (48C) to arrest biological activity, red cells treated with
lysis buffer (BioLegend, San Diego, Calif), and samples washed before flow
cytometric acquisition. In preliminary work, cell surface markers were used to
define monocyte populations (CD14, BD Pharmingen, USA) and estimate
neutrophil function (CD66b, Stemcell Technologies, Canada). Compensation
beads (BDBiosciences, USA)were used to create compensationmatrices. Cell
populations of interest were identified by sequential cell gating strategies.
Samples were acquired using a BD LSRII flow cytometer equipped with three
lasers (405 nm, 488 nm, and 633 nm; Becton Dickinson, USA) using FACS-
Diva (version 6.1, BD Biosciences, USA) and FlowJo (version 10.7, Tree Star,
USA) flow cytometry software.
Statistics
Data were examined for normality before applying appropriate tests. All
patient samples were analyzed pairwise (P4 peptide vs. vehicle or peptide
control). Mixed model regression analyses were used to allow the hierarchical
nature of patient sampling (one patient repeatedly sampled three times). Three
mixed models were used for the main analyses: model one had neutrophil
bacterial killing (%) as the dependent variable, phase of infection (early, latent,
convalescent) and group (P4 peptide, control) as fixed effects, and patient as
random effect. Model two had neutrophil intraphagosomal reporter bead
association as dependent variables, phase of infection (early, latent, convales-
cent), group (P4 peptide, control), time (0, 10, 20, 30, 45, 60min), and
interaction between group and time as fixed effects, and patient as random
effect. Model three had intraphagosomal reporter bead oxidation ratio as the
dependent variable with fixed and random effects as per model 2. The
differences between P4 peptide and control in mean of those outcomes at
different time points together with 95% confidence interval (CI) were derived
from the mixed models. Mixed model regression assumes that missing values
are at random.Mann–WhitneyU test was used when normality assumption was
violated. All data were analyzed using STATA 13.1 (Statacorp, USA).
RESULTS
Patient recruitment—clinical details and microbiology
Fifty-four patients were recruited to this study; 30 (55.6%)
were men and median age was 63.5 (interquartile range [IQR]
53–75). Fifty-two patients were of white ethnic origin, one
Asian, and one black. There were 17 smokers and median body
mass index was 27.3 (IQR 24.0–31.3). Premorbid status was
quantified using Charlson Index score (22) (median 2, IQR 1–
3). The most common premorbid conditions were hypertension
(14), type 2 diabetes mellitus (11), chronic obstructive pul-
monary disease (10), and ischemic heart disease (7). The
median Acute Physiology and Chronic Health Evaluation II
score was 19 (IQR 14–23). The median sequential organ failure
assessment score at critical care admission was 8 (IQR 5–10).
Table 1 describes illness severity parameters at each phase of
infection. No patients were readmitted to critical care between
latent and convalescent phases. Table 2 describes clinical out-
comes in this patient cohort. Thirty-eight patients had positive
microbiological samples (17 positive blood cultures, 9 bron-
choalveolar lavage, 9 tracheal aspirate, 12 sputum, 9 urine, and
18 abdominal swabs). The most common organisms identified
by blood culture were Escherichia coli (9), S pneumoniae (3),
and Klebsiella species (2). The source of infection was respir-
atory in 26 patients, abdominal in 21, and urogenital in 7. In
common with previous work (23), microbiological yield was
lower for respiratory infection (16/26) compared with that for
abdominal (16/21) and urogenital (6/7) infections, P¼ 0.043
(Kruskal–Wallis). In our cohort, 11/16 samples from patients
with respiratory infection grew gram-positive organisms.
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Eleven healthy volunteers were recruited to this study (six
males) with a median age of 21 (IQR 21–27). All of the healthy
volunteers were of white ethnic origin; there were no smokers
and median body mass index was 24.5 (IQR 22.1–28.3). The
volunteers had no premorbid conditions (median Charlson
Index score 0, IQR 0–0). Three samples of venous blood were
taken at intervals matched to that of the critical care patients
(i.e., time 0, 1 week later, and 3–6 months later).
Opsonophagocytosis assay: P4 peptide stimulated
increased bacterial killing
Neutrophil bacterial killing was 54.9% higher in P4-stimu-
lated cells compared with that in paired controls (24.13% vs.
15.57%, P< 0.001). There was no interaction between P4
peptide effect and phase of infection, such that stimulated
neutrophils demonstrated increased bacterial killing (8.55%,
P< 0.001) in early, latent, and convalescent infections (Fig. 1).
Raw data and details of the mixedmodel regression analysis are
provided in the Supplemental Digital Content, http://links.
lww.com/SHK/A443 (opsonophagocytosis assay analysis).
There was no difference between DEPC and M12-1 peptide
control, 16.65% versus 14.78%, P¼ 0.366 (Fig. S3, Supple-
mental Digital Content, http://links.lww.com/SHK/A443). In
the mixed model regression analysis, the source of infection
(respiratory 26, abdominal 21, urogenital 7) was not associated
with P4 peptide activity. In addition, smoking status did not
impact upon phagocytic function in this cohort. However, phase
of infection was independently associated with baseline bac-
terial killing and was significantly increased in the latent and
convalescent phase samples compared with early phase
samples. We found no significant difference in mean of neu-
trophil bacterial killing between patients with positive micro-
biology and patients with negative microbiology in early phase
samples in either control (14.15% vs. 17.89%, P¼ 0.208) or
P4 peptide–stimulated experiments (23.49% vs. 26.69%,
P¼ 0.273), unpaired t tests. In an exploratory analysis, clinical
laboratory white cell, neutrophil, and platelet counts were not
associated with baseline neutrophil bacterial killing or response
to P4 peptide in early phase samples (Tables S1 and S2,
Supplemental Digital Content, http://links.lww.com/SHK/
A443). This study was not adequately powered to formally
investigate the effect of P4 on samples from healthy volunteers,
but the results were consistent with the patient samples: P4
peptide leads to significantly increased mean of neutrophil
bacterial killing in blood sample one (day 0: 37.7% vs.
27.9%, P< 0.001, CI 7.0 – 12.6), blood sample two (day 7:
34.4% vs. 24.5%, P< 0.001, CI 7.0–12.6), and blood sample
three (month 3: 34.0% vs. 24.2% P< 0.001, CI 7.0–12.6),
mixed model regression analysis. Thus, baseline (vehicle con-
trol) neutrophil activity was initially lower in patient samples
before recovery toward healthy volunteer levels (early 15.5%,
latent 20.1%, and convalescent 23.2%; Fig. 1).
Whole blood phagocytosis assay: P4 peptide stimulates
increased reporter bead association and oxidation
P4 peptide stimulation significantly increased intraphagoso-
mal bead association (Fig. 2A) and intraphagosomal bead
oxidation (Fig. 2B) compared with paired vehicle control.
Raw data and details of the mixed model regression analysis
are provided in the Supplemental Digital Content, http://link-
s.lww.com/SHK/A443 (whole blood phagocytosis assay: neu-
trophil–bead association analysis; and whole blood
phagocytosis assay: neutrophil intraphagosomal reporter bead
oxidation analysis). A significant interaction was found
between duration of incubation and P4 peptide stimulation
in both reporter bead association and oxidation analyses. In
these mixed model regression analyses, source of infection
(respiratory 21, abdominal 17, and urogenital 6) was not
independently associated with P4 peptide activity but baseline
(vehicle control) bead association and oxidation were signifi-
cantly decreased in the latent and convalescent phases of
infection. There was no significant difference in bead associ-
ation or oxidation (area under the curve calculations) between
patients with positive microbiology and patients with negative
microbiology in early phase samples exposed to vehicle control
and P4 peptide (unpaired t tests). Additionally, in a nonpowered
cohort of healthy volunteers, treatment with P4 peptide stimu-
lated increased neutrophil–bead association compared with
vehicle control (Fig. S4, Supplemental Digital Content,
http://links.lww.com/SHK/A443).
Neutrophil CD66b expression
Neutrophils with increased expression of CD66b are associ-
ated with an upregulated respiratory burst in samples isolated
from patients with severe sepsis (24). Baseline CD66b was
higher in early phase samples compared with that in latent
phase samples (Fig. 3A) and this was associated with greater
neutrophil–bead association (Fig. 3B). There was no difference
TABLE 1. Illness severity and required organ support in early, latent,
and convalescent phases of infection
Parameter
Early
(n¼54)
Latent
(n¼39)
Convalescent
(n¼18)
SOFA score 8 (5–12) 2 (1–5) 0 (0–0)
Mechanical ventilation 35 (64.8%) 18 (46.2%) 0 (0%)
Cardiovascular support 36 (66.7%) 4 (10.3%) 0 (0%)
Renal replacement therapy 7 (13.0%) 3 (7.5%) 0 (0%)
The table demonstrates the change in SOFA score (median, IQR) in each
phase of infection and the number (%) of patients who required
mechanical ventilation, cardiovascular support (noradrenaline 31/36),
and renal replacement therapy. A total of 54/54 early, 29/39 latent, and
0/18 convalescent phase blood samples were taken with patients on
critical care wards. IQR indicates interquartile range; SOFA, sequential
organ failure assessment.
TABLE 2. Clinical outcomemeasures from critical care patient cohort
(n¼54)
Group Independent variable Median IQR
Organ support (days) Mechanical ventilation 6 0–10
Cardiovascular support 7 0–15
Length of stay (days) Critical care 9 5–16
Hospital 20 11–40
Mortality Critical care 14 (25.9%)
Hospital 18 (34.0%)
28 days 18 (34.0%)
The table displaysmedian and IQR values for organ support and length of
stay variables. For mortality values, the table displays n (%). IQR
indicates interquartile range.
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in expression between samples exposed to P4 peptide and
vehicle control.
Monocyte activity
Monocytes were identified by cell surface expression of
CD14 in 51/94 of blood samples taken from patients for the
whole blood phagocytosis assay. Seven samples identified
<750 monocytes and were excluded from the analysis. P4
peptide–stimulated monocytes had significantly increased
intraphagosomal reporter bead association in early, latent,
and convalescent phases of sepsis by 8.3% (CI 3.4–13,
P¼ 0.001). Monocyte oxidation ratio was significantly
increased in samples exposed to P4 peptide compared with
that in vehicle control (1.39 vs. 1.05, CI 0.23–0.44, P< 0.001).
Raw data and details of the mixedmodel regression analysis are
provided in the Supplemental Digital Content, http://links.
lww.com/SHK/A443 (whole blood phagocytosis assay: mono-
cyte-bead association analysis; and whole blood phagocytosis
assay: monocyte intraphagosomal reporter bead oxidation
analysis).
DISCUSSION
We found that augmented passive immunotherapy ex vivo
using P4 peptide stimulation significantly increased neutrophil
bacterial killing in samples from patients with severe sepsis.
FIG. 1. P4 peptide increases neutrophil bacterial killing in early,
latent, and convalescent phases of infection (adjusted analysis).
The figure demonstrates the mixed model adjusted analysis for bacterial
killing index (point estimate and 95% confidence interval) for neutrophils
exposed to P4 peptide compared with that for vehicle (DEPC water) control
in the opsonophagocytosis killing assay in patients admitted to critical
care with severe sepsis. Killing index describes how the addition of neutrophils
to complement and immunoglobulin opsonized Streptococcus pneumoniae
decreases subsequent bacterial growth—calculated as follows: (1$ [colony-
forming units experimental well)]/[colony-forming units opsonized non-neu-
trophil control well])%100. The addition of P4 peptide increased the mean
neutrophil bacterial killing compared with vehicle (DEPC water) control in
early (24.2 vs. 15.5, P<0.001), latent (28.7 vs. 20.1, P<0.001), and con-
valescent (31.8 vs. 23.2, P<0.001) phases of infection. DEPC indicates
diethylpyrocarbonate.
FIG. 2. P4 peptide increases intraphagosomal reporter bead and oxidation association in early, latent, and convalescent phases of severe
infection. A, The mixedmodel adjusted mean proportion (95% confidence interval) of neutrophils associated with an intraphagosomal reporter bead at 0, 10, 20,
30, 45, and 60min in the early, latent, and convalescent phases of infection. B, The mixed model adjusted mean oxidation ratio (95% confidence interval) of
intraphagosomal reporter beads associated with neutrophils at 0, 10, 20, 30, 45, and 60min in the early, latent, and convalescent phases of infection.
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This effect was independent of the source, microbiological
status, and phase of infection. These data are corroborated by
the whole blood phagocytosis assay that demonstrated P4-
mediated increase in intraphagosomal reporter bead association
and oxidation. This study demonstrates evidence that aug-
mented passive immunotherapy has promise as a potential
therapeutic strategy for patients with severe infection.
We recruited patients admitted to critical care with severe
infection with a wide range of comorbidities, infecting patho-
gens, severity of illness, and age. Therefore, our cohort represents
a broad spectrum of critically ill patients who could potentially
benefit from treatment with augmented passive immunotherapy.
Importantly, we have demonstrated a persistent response to P4
peptide in the latent phase of sepsis. Downregulation of the
immune system leaves patients prone to secondary hospital-
acquired infection, so this strategy of phagocyte stimulationmay
also benefit patients during later stages of disease (16).
Historically, adjuvant immunotherapies have failed to
improve outcomes for patients with community-acquired
pneumonia and sepsis (6). However, there is increasing
focus on immunostimulatory therapies (25) for infection
with recent work exploring the efficacy of interleukin-7 and
programmed death ligand 1 (26) in modulating T-cell
responses and granulocyte-macrophage colony-stimulating
factor (NCT01653665) and interferon-g (NCT01649921) in
modulating innate immune responses. Our study supports the
addition of augmented passive immunotherapy with P4 peptide
to the list of potential immunostimulatory adjuvant therapies
for severe infection. Treatment with augmented passive immu-
notherapy has previously been shown to rescue moribund septic
mice either alone or in combination with antibiotics (9). The
risk of immune hyperstimulation and organ injury is of concern
for immunostimulatory therapies (27). However, P4 peptide
does not stimulate inflammatory cytokine release ex vivo (15)
and activated neutrophils can be retained and ‘‘deprimed’’
within the lungs (28). This mechanism of depriming is reduced
for patients with adult respiratory distress syndrome; therefore,
the potential detrimental effects of P4 peptide in this specific
context require further investigation.
We used two robust methods to determine phagocytic
activity. First, the opsonophagocytosis killing assay is an
established and standardized method (29), widely used to
compare phagocytic function in vaccine efficacy testing (30)
and applied in previous work with P4 peptide (7, 8, 12, 15). As
previously described (15), P4-mediated effects on phagocyte
bacterial uptake depend on pathogen opsonization. Our study
investigated S Pneumoniae, but a previous in vitro study has
demonstrated that P4 peptide can increase phagocytic uptake of
opsonized gram-positive and gram-negative bacteria (8). We
used pooled human IVIG as a standardized opsonin in our
opsonophagocytosis killing assay. Future clinical investigation
could use P4 peptide administered with human IVIG as an
empirical opsonin against a range of bacteria (6). We used a
secondary whole blood phagocytosis assay to complement the
opsonophagocytosis assay using silica beads opsonized with
human immunoglobulin. The aims of this assay were to reduce
sample preprocessing and attempt to maintain the influence of
inflammatory mediators. We chose a kinetic assay (multiple
incubation intervals) to determine how P4 peptide influenced
both the magnitude and the timing of oxidative burst. Incu-
bation intervals were based on previous work (21, 31) that
demonstrates maximal oxidative burst at 30min of exposure to
the phagosome.
While both the opsonophagocytosis and whole blood phag-
ocytosis assays demonstrated that P4 peptide stimulation aug-
mented neutrophil activity, there were differences in baseline
(nonstimulated) neutrophil activity at different phases of infec-
tion. Downregulation of the immune system and impaired
neutrophil activity has been observed after an initial hyper-
immune response to infection—characterized by the ‘‘compen-
satory anti-inflammatory response syndrome’’ model of
immune activity (32). Our whole blood phagocytosis assay
data demonstrated this effect, but the opsonophagocytosis assay
did not (Figs. 1 and 2). We hypothesized that density isolation
and purification of neutrophils in the opsonophagocytosis assay
would preferentially select mature neutrophils (33) and dis-
carded lower density, less mature cells. We therefore used
FIG. 3. Neutrophil CD66b expression is lower in latent infection and
significantly associated with intraphagosomal reporter bead associ-
ation. A, Neutrophil 66B expression (median, IQR) in early and latent phases
of infection. There was a significant difference between the three phases
of infection (H[2]¼8.43, P¼0.015), Kruskal–Wallis rank test. Mean fluor-
escence intensity was significantly decreased in blood samples taken in latent
phase infection (median 15,200 vs. 25,411, P¼0.002) compared with that in
blood samples taken in early phase infection in patients admitted to critical
care; Mann–WhitneyU test. B, Neutrophil association with beads after 45-min
incubation compared with mean fluorescence intensity of cell surface 66B
expression in early and latent phases of infection. Linear regression analysis
demonstrated a significant association between logMFI and neutrophil–
bead association (F[1, 45]¼18.93, P<0.001, R2¼0.306). IQR indicates
interquartile range.
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neutrophil CD66b expression, a marker associated with integ-
rin-mediated adhesion and generation of reactive oxygen
species (24), as a surrogate for neutrophil maturity in our
whole blood assay. In support of our hypothesis, we observed
significantly decreased CD66b expression in the latent phase of
infection and significant correlation between neutrophil expres-
sion and association with intraphagosomal reporter beads (Fig.
3). In addition, we observed decreased monocyte–bead associ-
ation in the latent and convalescent phases of infection using
our whole blood phagocytosis assay. These results, coupled
with previous evidence (33), suggest that density isolation of
neutrophils limited our ability to measure the compensatory
anti-inflammatory response using the opsonophagocytosis
assay. An alternative neutrophil purification technique (e.g.,
magnetic negative cell selection) could mediate for this effect
but requires further investigation.
We used the M12-1 fragment of streptococcal group A
emm12 protein, a relevant immunogenic peptide control that
has been described as a virulence factor for streptococcal group
A infection (34) and induces adaptive immunogenic responses
in mice (35). We found no increase in neutrophil bacterial
killing using this control peptide so pragmatically used DEPC
water as the vehicle control for the remainder of the study, as
per previously published work (14, 15). For the whole blood
phagocytosis assay we noted convergence of results after
60-min incubation between P4 peptide and vehicle control–
stimulated samples. For oxidation ratio we highlighted the
plateau in oxidation ratio observed using this method. Vehicle
control samples reached this plateau but at a slower rate than
samples stimulated with P4 peptide. There was also a reduced
but still significant difference in neutrophil–bead association at
60min; this could be due to neutrophil saturation (only a
proportion of neutrophils will associate with beads) or digestion
of beads within the phagolysome, but these hypotheses require
further investigation. The purpose of this study was to measure
cellular response to P4 peptide; as such, we did measure
additional inflammatory mediators. Previous work demon-
strates that P4 peptide stimulation does not influence cellular
release of a number of inflammatory cytokines (15). Future
work should seek to determine the influence of inflammatory
mediators on P4 peptide activity.
There was a relatively high dropout for convalescent samples
in our cohort. Mortality accounted for 18/36 of dropouts, but
other patients were too unwell to attend or declined our
invitation citing multiple other hospital appointments—this
highlights the persistent morbidity often seen after critical
illness. The purpose of the healthy volunteer cohort was to
standardize study assays (healthy volunteer P4 peptide activity
is previously published (15)). The small number of samples and
differences in volunteer demographics (age, body mass index,
and comorbidities) limit our ability to directly compare patient
and volunteer samples and draw conclusions about the presence
and onset of compensatory anti-inflammatory response syn-
drome in our patient cohort. In addition, the demographic
variation of our study group was limited (52/54 patients were
whites); this limits our ability to extrapolate our results to a
more diverse cohort. Currently, this therapeutic strategy is
subject to preclinical toxicology investigations in preparation
for early phase clinical trials. This study will guide future
clinical studies as we seek to further refine the target patient
population.
CONCLUSION
In conclusion, augmented passive immunotherapy using P4
peptide significantly increased phagocytic killing in samples
taken from patients admitted to critical care with severe infec-
tion. The microbiological opsonophagocytic assay was sup-
ported by a flow cytometric whole blood assay that
demonstrated increased intraphagosomal reporter bead associ-
ation and oxidation in both neutrophils and monocytes. P4
peptide boosted the innate immune response to infection,
enhancing bacterial killing by key immune effector cell popu-
lations and demonstrating clear potential as a future treatment
of the most common causes of severe infection.
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